华润双鹤(600062) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was approximately ¥2.62 billion, representing a 0.55% increase compared to the same period last year[3]. - Net profit attributable to shareholders was approximately ¥350.53 million, a decrease of 11.83% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was approximately ¥335.14 million, an increase of 14.84% compared to the previous year[3]. - Basic earnings per share for the quarter were ¥0.3370, down 13.46% from ¥0.3894 in the same period last year[4]. - Total operating revenue for the first three quarters of 2024 reached CNY 8,548,241,751.78, a slight increase of 1.18% compared to CNY 8,448,408,526.04 in the same period of 2023[15]. - Net profit attributable to shareholders of the parent company for the first three quarters of 2024 was CNY 1,397,067,248.19, up from CNY 1,382,246,523.60 in 2023, reflecting a growth of 1.07%[16]. - The net profit for the first three quarters of 2024 was CNY 1,411,764,462.20, compared to CNY 1,383,715,041.74 in 2023, indicating a growth of 2.02%[16]. - Earnings per share for the first three quarters of 2024 were CNY 1.3596, slightly higher than CNY 1.3484 in the same period of 2023[16]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥15.43 billion, a decrease of 9.10% from the previous year[4]. - As of September 30, 2024, the total assets of China Resources Double Crane Pharmaceutical Co., Ltd. amounted to CNY 16,545,313,485.37, a decrease from CNY 18,202,533,078.60 at the end of 2023[11]. - The company's current assets totaled CNY 7,283,187,488.04, down from CNY 9,381,551,056.79 in the previous year[11]. - The total liabilities decreased to CNY 4,567,895,900.83 from CNY 4,779,185,633.11, a reduction of approximately 4.4%[12]. - Total liabilities as of September 30, 2024, amounted to CNY 5,656,590,501.89, an increase from CNY 5,303,247,717.87 at the end of 2023[13]. - The company's total non-current liabilities rose significantly to CNY 1,088,694,601.06 from CNY 524,062,084.76 in the previous period[13]. - The company's total equity decreased to CNY 11,977,417,584.54 from CNY 13,423,347,445.49, a decline of about 10.8%[12]. - The company's total equity decreased to CNY 10,888,722,983.48 from CNY 12,899,285,360.73, reflecting a decline of approximately 15.6%[13]. Cash Flow - The net cash flow from operating activities for the year-to-date was approximately ¥1.46 billion, an increase of 16.64% year-on-year[3]. - The total cash inflow from operating activities for the first three quarters of 2024 was approximately ¥8.04 billion, a decrease of 2.14% compared to ¥8.22 billion in the same period of 2023[17]. - The net cash flow from operating activities increased to approximately ¥1.46 billion, up 16.66% from ¥1.25 billion in the previous year[17]. - Cash inflow from investment activities was approximately ¥1.72 billion, slightly down from ¥1.78 billion in the same period last year[18]. - The net cash flow from investment activities turned positive at approximately ¥1.10 billion, compared to a negative cash flow of approximately -¥637 million in 2023[18]. - Cash outflow from financing activities significantly increased to approximately ¥3.71 billion, compared to ¥747 million in the same period last year[18]. - The net cash flow from financing activities was negative at approximately -¥3.07 billion, worsening from -¥433 million in 2023[18]. - The ending balance of cash and cash equivalents was approximately ¥2.70 billion, down from ¥2.81 billion at the end of the same period last year[18]. - The company received approximately ¥640 million in cash from borrowings during the financing activities, marking a new source of funds[18]. - The company paid approximately ¥1.28 billion in dividends and interest, significantly higher than ¥460 million in the previous year[18]. Shareholder Information - The company reported a total of 40,648 common shareholders at the end of the reporting period[6]. - The largest shareholder, Beijing Pharmaceutical Group Co., Ltd., holds 60.21% of the shares[6]. Research and Development - Research and development expenses increased to CNY 472,694,977.58 in 2024, compared to CNY 413,435,277.07 in 2023, marking a rise of 14.3%[15].